北陆药业(300016) - 2025 Q4 - 年度业绩预告

Financial Projections - The estimated net profit for 2025 is projected to be between 87 million and 130 million CNY, representing a year-on-year growth of 537.28% to 852.26%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 33 million and 49.5 million CNY, indicating a growth of 134.14% to 251.20% compared to the previous year[5] - The impact of non-recurring gains and losses on the net profit attributable to shareholders is estimated to be between 50 million and 80 million CNY[8] Business Strategy and Performance - The company has implemented a dual-driven strategy of chemical and traditional Chinese medicine, leading to continuous revenue growth in both domestic and overseas markets[8] - Operational management efficiency has improved due to ongoing cost reduction and efficiency enhancement measures, significantly boosting company performance[8] - The redemption and delisting of "Beilu Convertible Bonds" in August 2025 have notably reduced financial expenses compared to 2024[8] Audit and Reporting - The company emphasizes that the performance forecast is based on preliminary calculations and has not yet been audited by the accounting firm[9] - Detailed financial data for the 2025 fiscal year will be disclosed in the company's annual report[9] Investor Advisory - The company urges investors to make cautious decisions and be aware of investment risks[9]